Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Hospital @ Home-Modell für die Behandlung von Leberzirrhose (H@H)

17. September 2026 aktualisiert von: Archita P. Desai, Indiana University

Das Hospital @ Home-Pflegemodell: Eine neuartige Gesundheitslösung für die Behandlung dekompensierter Zirrhose

The purpose of this study is to work with patients diagnosed with end-stage liver disease to understand their perspectives on the Health at Home (H@H) Program, including desired outcomes and expectations, perceived barriers, and drivers. H@H is an emerging model of home-based care, designed to extend traditional, inpatient hospital care which may address these needs. Through H@H, acute medical care services as well as ancillary care such as rehabilitation therapy can be delivered in the home. The study is divided into three phases: Phase 1 occurs while the participant is an inpatient. Phase 2 is when the actual H@H program takes place as part of the participant's clinical care. The study team will not be involved in the Phase 2 - H@H program as it will be conducted by the clinical staff. Phase 3, at which point the participant enters a rehabilitation phase to transition the patient to self-management, involves a research jam session with the participant and caregiver to assess the value of the program.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Hospital at Home (H@H) as an emerging model of care is designed as an extension for traditional inpatient hospital care. Patients experiencing certain medical conditions normally requiring admission to an inpatient hospital can instead consent to receive acute care treatment in their homes. Prior studies have shown success of this model through demonstration of clinical and economic efficacy and feasibility, as well as greater satisfaction with care for patients, their family members and their providers. Since November 2020, Centers for Medicare and Medicaid Services has provided a waiver for H@H services. Similarly in 2020, Indiana University Health (IUH) introduced the Hospital at Home (H@H) Program for its beneficiaries to increase hospital capacity during the Public Health Emergency. Through this program, primary medical management services as well as ancillary services such as Occupational Therapy, Physical Therapy, and diagnostic testing can be delivered in the home. This model has been successful used at IUH to management patients with moderate COVID-19 infection, common infectious diseases, and decompensated heart failure.

In the realm of liver disease, acute decompensations of chronic liver disease often require hospitalizations for acute management. In certain clinical scenarios, while the initial 24-48 hour period may require the intensive management offered in an acute care hospital, the remaining hospital days represent less acute and/or intense needs such as continued administration of IV medications, monitoring for safe transition to oral medications and/or daily lab monitoring for period of time. We hypothesize that services through the IUH H@H program can offer equally safe and effective for these clinical scenarios while improving patient satisfaction, reducing care-giver burden, being cost-saving and improving access to acute care hospital services to other patients. We also hypothesize that completing the acute care management in the home setting will lead to more effective transition to chronic management as measured by subsequent 30-day readmissions and 30-day emergency room visits leading to reduced overall cost of health care. As a next step in expansion, the IUH H@H team is partnering with the PI and IUH Hepatology team to manage select patients with chronic liver disease (CLD). The overall goal of this proposal is to assess whether IUH's H@H program represents a novel care delivery model in cirrhosis that is safe, improves patient and caregiver experience as well as reduces HCU in the high-risk, CLD population.

Studientyp

Interventionell

Einschreibung (Geschätzt)

30

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Regia Weber
  • Telefonnummer: 317-278-3584
  • E-Mail: reginaw@iu.edu

Studieren Sie die Kontaktsicherung

  • Name: Archita Desai, MD
  • Telefonnummer: (317) 278-1664
  • E-Mail: desaiar@iu.edu

Studienorte

    • Indiana
      • Indianapolis, Indiana, Vereinigte Staaten, 46202
        • Rekrutierung
        • IU School of Medicine
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Enrolled into IUH's H@H program
  • At least 18 years of age
  • Chronic liver disease/cirrhosis based on characteristic clinical, laboratory, and imaging findings
  • English speaking
  • Able to provide consent
  • Caregiver able to be present during the acute phase of care (first 48 hours post-hospital discharge)
  • Able to perform activities of daily living independently
  • Lives within IU Health Home service area

Exclusion Criteria:

  • Unable to complete study questionnaires due to neurocognitive disease, legal blindness or hearing loss
  • Transplant of organ other than liver
  • Pregnant
  • Incarcerated
  • New hemodialysis
  • Blood pressure < 90/60, Pulse > 120, O2 > 6L or >2L above baseline
  • HIV+/CD4 count < 200
  • Receiving hospice services
  • Concurrent enrollment in a related research study

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Versorgungsforschung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Sonstiges: Decompensated Cirrhotics

Phase 1:

  • two questionnaires to assess patient reported outcomes
  • an open-ended patient interview using a variety of patient-engagement methods to assess program expectations

Phase 2:

• completion of the Hospital at Home (H@H) program as part of clinical care. In brief, the Hospital at Home program (H@H) is an innovative care delivery method that aims to provide hospital-level care at home and facilitate the transition care from the hospital to the home.

Phase 3:

  • researchers engage virtually to discuss actual experience, outcomes, and challenges. These will be semi-structured interviews about their perspectives on the program, including desired outcomes and expectations and perceived barriers and drivers and will last about two hours.
  • complete four questionnaires relating to quality of life.

Structure of Care in IUH H@H Program: The IUH H@H program allows patients to be cared for at home using home remote monitoring devices, travel laboratory services and both in-person and virtual rounding by the health care team. The team includes registered nurses (RN), advanced practice provider (APP, nurse practitioner and physician assistants) and hospitalist physician. Care at home is divided into 4 consecutive phases after initial hospitalization: (1) evaluation/planning, (2) acute, (3) recovery, and (4) rehabilitation. All patients are sent home with a RPM tablet used to obtain vital signs, send messages between patient and RN, & perform video visits. The device is Bluetooth enabled and does not require WiFi or a phone line. All data obtained is automatically pulled into the electronic medical record. The RN uses a device which enables remote physical exams, i.e., obtain heart, lung and bowel sounds, pictures (wounds, lines, etc.) for review by APP/MD.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
Number of participants enrolled into program
Zeitfenster: Phase 1 Baseline
Phase 1 Baseline
Reason for enrollment failure
Zeitfenster: Phase 1 Baseline
Phase 1 Baseline

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of participants with follow-up consultations during Phase 2
Zeitfenster: During H@H program and up to and including 90 days after program completion
During H@H program and up to and including 90 days after program completion
Number of participants with services utilized in the home during Phase 2
Zeitfenster: During H@H program and up to and including 90 days after program completion
During H@H program and up to and including 90 days after program completion
Number of participants with ED visits
Zeitfenster: During H@H program and up to and including 90 days after program completion

ED visits, including repeat visits, will be tracked

During H@H program and up to and including 90 days after program completion
Number of participants with rehospitalization
Zeitfenster: During H@H program and up to and including 90 days after program completion
During H@H program and up to and including 90 days after program completion
Number of participants with a liver transplant
Zeitfenster: 30 and 90 days after H@H program completion
30 and 90 days after H@H program completion
Number of participants with hospice enrollment
Zeitfenster: 30 and 90 days after H@H program completion
30 and 90 days after H@H program completion
Rate of Mortality
Zeitfenster: up to 90 days after H@H program completion
up to 90 days after H@H program completion
PSQ 18
Zeitfenster: at 2 weeks after H@H program completion

Patient Satisfaction Questionnaire

at 2 weeks after H@H program completion
Telemedicine Questionnaire
Zeitfenster: at 2 weeks after H@H program completion
at 2 weeks after H@H program completion
ZBI-12
Zeitfenster: at 2 weeks after H@H program completion

Zarit Burden Interview Questionnaire

at 2 weeks after H@H program completion
Promis 29+2
Zeitfenster: up to 90 days after H@H program completion

change in health related quality of life

up to 90 days after H@H program completion

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

10. Mai 2024

Primärer Abschluss (Geschätzt)

30. September 2028

Studienabschluss (Geschätzt)

31. Dezember 2028

Studienanmeldedaten

Zuerst eingereicht

30. April 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

30. April 2024

Zuerst gepostet (Tatsächlich)

2. Mai 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

22. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

17. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 21905

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .